Skip to Main Content

What happens to Celgene (CELG) if the proposed $74 billion acquisition by Bristol-Myers Squibb (BMY) dies?

“That would be a total nightmare, a worst-case scenario for Celgene, so right now, the directors on its board are doing everything they can to prevent the deal from unraveling,” said Jason Aryeh, founder and partner at JALAA Equities, an activist hedge fund.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • why panic,though i have a fair stake in celgene,and welcome the deal,our pipeline ought to suffice for the future.If not,than what is all the hype about Bristol Myers looking toward the future via the celgene pipeline.It the deal goes south,why should Celgene given their future drug prospects.These scare tactics are just short term profit driven behaviors.

Comments are closed.